81 related articles for article (PubMed ID: 20878069)
1. Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer.
Lo Nigro C; Monteverde M; Riba M; Lattanzio L; Tonissi F; Garrone O; Heouaine A; Gallo F; Ceppi M; Borghi F; Comino A; Merlano M
Int J Oncol; 2010 Nov; 37(5):1219-28. PubMed ID: 20878069
[TBL] [Abstract][Full Text] [Related]
2. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
Napieralski R; Ott K; Kremer M; Specht K; Vogelsang H; Becker K; Müller M; Lordick F; Fink U; Rüdiger Siewert J; Höfler H; Keller G
Clin Cancer Res; 2005 Apr; 11(8):3025-31. PubMed ID: 15837757
[TBL] [Abstract][Full Text] [Related]
3. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
Kim HK; Choi IJ; Kim CG; Kim HS; Oshima A; Michalowski A; Green JE
PLoS One; 2011 Feb; 6(2):e16694. PubMed ID: 21364753
[TBL] [Abstract][Full Text] [Related]
4. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
6. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
7. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
8. Effects of IGF2BP2, KCNQ1 and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen.
Liu X; Chen Z; Zhao X; Huang M; Wang C; Peng W; Yin J; Li J; He G; Li X; Zhu X
Pharmacogenomics; 2015; 16(9):959-70. PubMed ID: 26115082
[TBL] [Abstract][Full Text] [Related]
9. Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients.
Zhong G; Li HK; Shan T; Zhang N
Genet Mol Res; 2015 Dec; 14(4):17228-34. PubMed ID: 26681216
[TBL] [Abstract][Full Text] [Related]
10. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
[TBL] [Abstract][Full Text] [Related]
13. Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression.
Cheng L; Qiu L; Wang M; Zhang R; Sun M; Zhu X; Wang Y; Wei Q
Mol Carcinog; 2017 Dec; 56(12):2706-2717. PubMed ID: 28796378
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
Geng R; Chen Z; Zhao X; Qiu L; Liu X; Liu R; Guo W; He G; Li J; Zhu X
PLoS One; 2014; 9(12):e116027. PubMed ID: 25545243
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
Ruzzo A; Graziano F; Kawakami K; Watanabe G; Santini D; Catalano V; Bisonni R; Canestrari E; Ficarelli R; Menichetti ET; Mari D; Testa E; Silva R; Vincenzi B; Giordani P; Cascinu S; Giustini L; Tonini G; Magnani M
J Clin Oncol; 2006 Apr; 24(12):1883-91. PubMed ID: 16622263
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin.
Shim HJ; Yun JY; Hwang JE; Bae WK; Cho SH; Lee JH; Kim HN; Shin MH; Kweon SS; Lee JH; Kim HJ; Chung IJ
Cancer Sci; 2010 May; 101(5):1247-54. PubMed ID: 20331623
[TBL] [Abstract][Full Text] [Related]
18. A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4'-epirubicin (FPEPIR). Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC).
Anticancer Res; 1992; 12(6B):1983-8. PubMed ID: 1295444
[TBL] [Abstract][Full Text] [Related]
19. Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
Liu JB; Jian T; Yue C; Chen D; Chen W; Bao TT; Liu HX; Cao Y; Li WB; Yang Z; Hoffman RM; Yu C
Anticancer Res; 2019 Apr; 39(4):1689-1698. PubMed ID: 30952707
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
Miura JT; Johnston FM; Thomas J; George B; Eastwood D; Tsai S; Christians KK; Turaga KK; Gamblin TC
J Surg Oncol; 2014 Sep; 110(3):302-6. PubMed ID: 24844210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
